Two Stroke-Prevention Procedures Equally Safe, But One Should Be Chosen Based On Age
July 31, 2017
A published report provides the final details on how two stroke-prevention procedures are safe and equally beneficial for men and women at risk for stroke, though their effectiveness does vary by age, say researchers at the University of Alabama at Birmingham (UAB) School of Public Health in collaboration with other North American stroke investigators.
In findings reported online in the New England Journal of Medicine (NEJM) May 26, the researchers say the age of patients made a difference in comparing the two prevention procedures, and physicians should consider this and many other factors when tailoring their treatment plans for patients at risk for stroke.
The study is part of the Carotid Revascularization Endarterectomy vs. Stenting Trial (CREST). It was presented in summary form at the International Stroke Conference in San Antonio, Texas, Feb. 26.
Stroke, the third-leading cause of death in the nation, is caused by an interruption in blood flow to the brain by a clot or bleeding. The carotid arteries on each side of the neck are the major source of blood flow to the brain. The buildup of cholesterol in the wall of the carotid artery, called atherosclerotic plaque, is one cause of stroke.
CREST compares endarteroctomy, a surgical procedure to clear blocked blood flow and prevent stroke, with carotid stenting, a newer procedure that involves threading a stent and expanding a small protective device in the artery to widen the blocked area and capture dislodged plaque.
The overall safety and efficacy of the two procedures essentially is the same with equal benefits for men and women, for patients who previously have had a stroke and for those who have not, researchers say. The most notable finding in the NEJM study is the role of patient age in accounting for differences in treatment outcomes, says George Howard, Dr.PH., chair of biostatistics in UAB's School of Public Health and a CREST co-investigator.
CREST investigators did see more heart attacks in the surgical group, 2.3 percent compared to 1.1 percent in the stenting group, and they did see more strokes in the stenting group, 4.1 percent versus 2.3 percent for the surgical group in the weeks following the procedure. Overall the study found a lower stroke rate following surgery and a lower heart-attack rate after stenting a year after their procedure.
"The age-difference issue is one of the most important findings of the study, though the two treatments really were practically identical in their benefit of patients at age 70, Howard says. "At younger and younger ages, the benefit of stenting became better and better than surgery. However, this benefit of stenting was offset by better outcomes of surgery at older and older ages."
CREST is one of the largest randomized stroke-prevention trials in history, involving 2,502 patients at 117 centers in the United States and Canada during a nine-year period. It is funded by the National Institute of Neurological Disorders and Stroke (NINDS) and led by Thomas G. Brott, M.D., of the Mayo Clinic in Jacksonville, Fla. Twenty-one CREST patients are enrolled in Alabama under the medical direction of William Jordan, M.D., chief of vascular surgery at UAB.
Because people with carotid atherosclerosis also usually have atherosclerosis in the coronary arteries that supply the heart, the CREST trial tracks the rate of heart attacks, in addition to stroke and death. The average age of CREST patients is 69.
In CREST, approximately half of the 2,502 patients had recent symptoms due to carotid disease such as a minor stroke, often called a transient ischemic attack (TIA), indicating a high risk for future stroke. The other half of patients had no symptoms, but they were found to have narrowing of the carotid artery on one of a variety of tests assessing stroke risk.
NINDS is committed to long-term follow-up of CREST patients to learn how best to prevent stroke. Partial funding for the study is supplied by Abbott, of Abbott Park, Ill., the maker of the stents.
Others from UAB involved in the study are Virginia Howard, Ph.D., an associate professor of epidemiology, and Jenifer Voeks, Ph.D., an assistant professor of epidemiology, both in the School of Public Health. Also involved are researchers at Lenox Hill Hospital in New York; Oregon Health Science University in Portland; Central Baptist Hospital in Lexington, Ky.; Hop de L'Enfant Jesus in Quebec City, Canada; University of Medicine and Dentistry of New Jersey in Newark; University of Maryland in Baltimore; Harvard Clinical Research Institute in Boston; University of California, Los Angeles.
About the UAB School of Public Health
The UAB School of Public Health is a community of scholars and professionals working and teaching in varied arenas of public health with the goal of fostering research and best practices crucial to the health of the United States and its peoples. The school offers more than 20 areas of study and manages dozens of research and community-service centers.
University of Alabama at Birmingham